A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
BioNTech SE
University of Alabama at Birmingham
Genmab
Parabilis Medicines, Inc.
National Institutes of Health Clinical Center (CC)
Eikon Therapeutics
Genmab
Alliance Foundation Trials, LLC.
858 Therapeutics, Inc.
Radiopharm Theranostics, Ltd
Eisai Inc.
AstraZeneca
Terremoto Biosciences Inc.
GlaxoSmithKline
Artios Pharma Ltd
Ensem Therapeutics
Eisai Inc.
PMV Pharmaceuticals, Inc
Mayo Clinic
Qilu Pharmaceutical Co., Ltd.
Eli Lilly and Company
AstraZeneca
Genmab
Children's Oncology Group
AstraZeneca
Arvinas Inc.
Revolution Medicines, Inc.
GlaxoSmithKline
DualityBio Inc.
Beijing Tide Pharmaceutical Co., Ltd